The Latin America, Middle East and Africa Sustained Release Excipients Market should witness market growth of 11.4% CAGR during the forecast period (2022-2028).
The increased physician comfort with the potential of continuous drug release to produce appropriate blood levels has also made the sustained release drug delivery systems practitioners preferred. There are numerous current initiatives to enhance the therapeutic effectiveness, bioavailability, and patient compliance of oral medications. To satisfy the increasing needs, numerous sustained-release oral medication delivery techniques have been created.
The market is being driven by an increase in the number of licensing agreements that have been signed for the generation of controlled-release medication forms in therapeutic applications such as oncology, oral vaccines, and CNS. Furthermore, because there are no delivery methods specially created for the juvenile population, they need distinct oral drug delivery systems from other segments of the population.
As a result, adult dose forms already in use are modified to treat juvenile patients. Various disorders that affect the elderly are treated with the help of sustained release medication delivery forms. Through the use of these drug-delivering devices, adherence to the medications can likewise be easily monitored.
Latin America to the fore of the region's health policies. This would enable both raising awareness about the bad quality of life that these diseases bring and recognition of better medication to be employed for treatment. Similarly, CVD is the leading cause of mortality in Brazil, which has resulted because of two reasons. The first is the development of urbanization- and globalization-related lifestyle changes, such as increased calorie consumption and decreased energy expenditure. The other is the quick aging of the population brought on by higher life expectancies and decreasing fertility.
The Brazil market dominated the LAMEA Sustained Release Excipients Market by Country in 2021; thereby, achieving a market value of $34.5 million by 2028. The Argentina market would exhibit a CAGR of 12% during (2022-2028). Additionally, The UAE market is estimated to witness a CAGR of 11.1% during (2022-2028).
Based on Route of Administration, the market is segmented into Oral, Transdermal, Vaginal, Intravenous, Ophthalmic, Subcutaneous, Intramuscular, and Others. Based on Product, the market is segmented into Polymers, Minerals, Sugars, Gelatin & Chitosan, and Others. Based on Technology, the market is segmented into Targeted Delivery, Implants, Wurster Technique, Transdermal, Micro Encapsulation, and Coacervation & Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BASF SE, International Flavors & Fragrances, Inc., Ashland Global Holdings Inc., Evonik Industries AG, Croda International Plc, Gattefossé, Merck Group, Pfizer, Inc., Novartis AG and AstraZeneca Plc.
The increased physician comfort with the potential of continuous drug release to produce appropriate blood levels has also made the sustained release drug delivery systems practitioners preferred. There are numerous current initiatives to enhance the therapeutic effectiveness, bioavailability, and patient compliance of oral medications. To satisfy the increasing needs, numerous sustained-release oral medication delivery techniques have been created.
The market is being driven by an increase in the number of licensing agreements that have been signed for the generation of controlled-release medication forms in therapeutic applications such as oncology, oral vaccines, and CNS. Furthermore, because there are no delivery methods specially created for the juvenile population, they need distinct oral drug delivery systems from other segments of the population.
As a result, adult dose forms already in use are modified to treat juvenile patients. Various disorders that affect the elderly are treated with the help of sustained release medication delivery forms. Through the use of these drug-delivering devices, adherence to the medications can likewise be easily monitored.
Latin America to the fore of the region's health policies. This would enable both raising awareness about the bad quality of life that these diseases bring and recognition of better medication to be employed for treatment. Similarly, CVD is the leading cause of mortality in Brazil, which has resulted because of two reasons. The first is the development of urbanization- and globalization-related lifestyle changes, such as increased calorie consumption and decreased energy expenditure. The other is the quick aging of the population brought on by higher life expectancies and decreasing fertility.
The Brazil market dominated the LAMEA Sustained Release Excipients Market by Country in 2021; thereby, achieving a market value of $34.5 million by 2028. The Argentina market would exhibit a CAGR of 12% during (2022-2028). Additionally, The UAE market is estimated to witness a CAGR of 11.1% during (2022-2028).
Based on Route of Administration, the market is segmented into Oral, Transdermal, Vaginal, Intravenous, Ophthalmic, Subcutaneous, Intramuscular, and Others. Based on Product, the market is segmented into Polymers, Minerals, Sugars, Gelatin & Chitosan, and Others. Based on Technology, the market is segmented into Targeted Delivery, Implants, Wurster Technique, Transdermal, Micro Encapsulation, and Coacervation & Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BASF SE, International Flavors & Fragrances, Inc., Ashland Global Holdings Inc., Evonik Industries AG, Croda International Plc, Gattefossé, Merck Group, Pfizer, Inc., Novartis AG and AstraZeneca Plc.
Scope of the Study
By Route of Administration
- Oral
- Transdermal
- Vaginal
- Intravenous
- Ophthalmic
- Subcutaneous
- Intramuscular
- Others
By Product
- Polymers
- Minerals
- Sugars
- Gelatin & Chitosan
- Others
By Technology
- Targeted Delivery
- Implants
- Wurster Technique
- Transdermal
- Micro Encapsulation
- Coacervation & Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- BASF SE
- International Flavors & Fragrances, Inc.
- Ashland Global Holdings Inc.
- Evonik Industries AG
- Croda International Plc
- Gattefossé
- Merck Group
- Pfizer, Inc.
- Novartis AG
- AstraZeneca Plc
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. LAMEA Sustained Release Excipients Market by Route of Administration
Chapter 5. LAMEA Sustained Release Excipients Market by Product
Chapter 6. LAMEA Sustained Release Excipients Market by Technology
Chapter 7. LAMEA Sustained Release Excipients Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- BASF SE
- International Flavors & Fragrances, Inc.
- Ashland Global Holdings Inc.
- Evonik Industries AG
- Croda International Plc
- Gattefossé
- Merck Group
- Pfizer, Inc.
- Novartis AG
- AstraZeneca Plc
Methodology
LOADING...
